Jessica Yingling

Loading...
    • Member Type(s): Expert
      Communications Professional
    • Title:Director, Corporate Communications
    • Organization:Fate Therapeutics
    • Area of Expertise:Stem Cells, Therapeutics, Biotechnology
    •  

    To become a ProfNet premium member and receive requests from reporters looking for expert sources, click here.

My Expertise

    My Expertise

      Area(s) of expertise: Stem Cells, Therapeutics, Biotechnology
      Summary of expertise:
      Fate has a unique approach to stem cell medicines. We develop small molecule and biologic drugs to modulate the body’s own stem cells to treat disease and restore health. We hope to accelerate the translation of stem cell research breakthroughs into much-needed new medicines for diseases and conditions that have limited treatment options. Fate also has the most advanced induced pluripotent stem cell (iPSC) technology. iPSCs are made by “reprogramming” fully differentiated mature cells, such as adult skin cells, to become pluripotent or stem-cell like and do not rely on the use of stem cells derived from embryos (ESCs). Because iPSCs can differentiate into any cell type, iPSCs are considered to be of great potential for disease research, preclinical testing and personalized cell replacement therapy.
      Blog/Web site: www.fatetherapeutics.com
      White paper/research:
      Drug Discovery Today: "Stem cell modulators (SCMs): a small molecule and biologic approach to stem cell therapeutics"
      20090825_(ddt)_stem_cell_modulators_a_small_mo.
      Awards/associations/memberships:
      - One of 50 of the Most Innovative Companies in the World by MIT's Technology Review - Named Top Technology of 2009 by The Scientist
      Prior media experience:
      Multiple experts available from industry and academia to discuss stem cell research and medicines

Profile TagsPlease separate tags with commas

  • Director, News Operations
    ProfNet
    @profnet
    NJ
  • Community Editor
    ProfNet Connect (PR Newswire)
    @editorev
    NJ

Comments

Blog Headlines

    No recent blog posts
    Loading...